Odelle Technology

13/05/2026

A very important NICE signal for AI diagnostics.

NICE has recommended .Spiro for NHS use during a 3-year evidence-generation period to support asthma and COPD diagnosis in primary care and community diagnostic centres.

This matters far beyond spirometry.

It shows that an AI diagnostic tool can enter NHS use before full evidence maturity — but only when it is placed inside a governed clinical pathway, with professional oversight, DTAC compliance, evidence generation and a clear NHS workforce/access rationale.

The company behind this is , now part of .

Congratulations to Marko Topalovic, Bart Swaelens, Prof. Wim Janssens, Prof. Marc Decramer and the wider ArtiQ/Clario team. ArtiQ has moved from Leuven respiratory AI innovation to a NICE-supported NHS evidence-generation pathway — that is a serious achievement.

The lesson for digital health and AI companies is simple:

NICE is not reimbursing “AI”.

NICE is asking whether the technology can help the NHS make better diagnostic decisions, closer to the patient, with less specialist bottleneck, safer oversight, and measurable evidence.

For companies in imaging AI, respiratory diagnostics, ophthalmology, neurology, pathology, oncology decision-support or community diagnostics, HTG776 is a blueprint.

The new reimbursement question is no longer only:

“Does the algorithm work?”

It is:

“Can the algorithm safely change the clinical pathway, reduce avoidable pressure on the system, and generate the evidence needed for routine adoption?”

That is why this decision is important.

11/05/2026

Bladder diagnosis has a pathway problem.
Too many patients with enter an invasive pathway, while many will not ultimately have cancer. At the same time, patients with previous bladder cancer often face repeated surveillance cystoscopies over the years.
That is why Nonacus’ GALEAS™ is potentially so interesting.
Its value is not simply that it is a urine-based molecular test.
Its value lies in changing the decision point before cystoscopy.
A non-invasive sample, targeted genomic analysis, and molecular risk stratification could help teams decide:
Who needs urgent ?
Who can be monitored more safely?
Who may avoid an unnecessary invasive procedure?
That is where diagnostics become health-system infrastructure.
The game changer is not the test tube.
It is the pathway shift:
From routine invasive investigation
to molecularly informed triage and surveillance.
For patients, that means less anxiety and fewer unnecessary procedures.
For clinicians, it means better prioritisation.
For hospitals, it means released urology capacity.
For payers, it means a clearer economic argument.
This is exactly where precision medicine becomes practical: not just detecting molecular signals, but changing clinical decisions in a congested real-world pathway. Rik Bryan, Doug Ward, James Catton, John Kelly, Rakesh Heer, Tom Powles, Nick James, Robert Huddart, Deborah Enting Bladder Cancer Advocacy Network The Royal Marsden NHS Foundation Trust Robert Huddart Morgan Rouprêt LORIOT Yohann

11/05/2026

NICE has just done something important for digital health in asthma.
In HealthTech guidance HTG778, NICE assessed 9 digital asthma self-management technologies:
— ICST
for parents ICST
— AsthmaTuner by MediTuner AB
Digital Health Passport — Tiny Medical Apps
JOE Digital Therapeutic — Ludocare
Luscii - an OMRON Healthcare service
— my mhealth
RDMP / Respiratory Disease Management Platform Aptar Digital Health
Asthma Smart — Smart Respiratory
NICE recommended 7 technologies for NHS use while further evidence is generated:
Asthmahub, Asthmahub for parents, Digital Health Passport, Luscii - an OMRON Healthcare service, myAsthma, RDMP and Smart Asthma.
This was not a simple “app review”.
NICE looked at whether digital asthma tools can improve standard asthma self-management by making personalised asthma action plans more accessible, usable and actionable.
The key economic question was:
Can these tools improve asthma control, reduce exacerbations, lower GP, emergency and hospital burden, and become cost-effective in real NHS practice?
NICE used an exploratory economic model and found that the technologies could be cost-effective if asthma control improves, but the evidence remains uncertain.
That is why this is an early-use recommendation rather than full routine adoption.
The technologies can be used in the NHS for 3 years while evidence is generated.
The real reimbursement story is this:
NICE is not valuing “an app”.Henrik Ljungberg Björn Nordlund Greg Burch,Matt Bourne Alexandra de la Fontaine Daan Dohmen Ayumu Okada Tom Wilkinson Simon Bourne Gael Touya Stephan Tanda Thomas Antalffy Richard Petho Teik Goh Judith Shore Sarah Sleet Andrew Whittamore
It is testing whether digital self-management can turn asthma action plans into something patients actually use, remember and act on — and whether that changes outcomes and NHS resource use.https://https://lnkd.in/emGTWC89

29/04/2026

https://odelletechnology.com/indirect-treatment-comparisons-in-france-why-has-breaks-multi-market-evidence-strategies/

Indirect Treatment Comparisons in France: Why HAS Exposes the Limits of Multi-Market Evidence Strategies For over a decade, market access teams have observed a persistent pattern: indirect treatment comparisons (ITCs) that satisfy the National Institute for Health and Care Excellence and align with....

26/04/2026

https://www.youtube.com/watch?v=nZ9Sqyb-sI0&t=783s

3 likes. "Podcast with Dr Lara Zibners and Thang Vo-Ta from Calla Lily Clinical Care"

27/01/2026

https://www.youtube.com/watch?v=Ax145T_THp8

Podcast with Jenny Rivers, Director of Research & Development at Barts Health NHS Trust and Dr Suthesh Sivapalaratnam, Clinical Senior Lecturer in Haematolog...

26/01/2026

How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It selectively rewards certain types of technologies, structurally disadvantages others, and—most c...

26/01/2026

How venture capital really works in MedTech and IVD. Academic evidence on VC risk pricing, reimbursement systems, DRGs and scalable exits.

26/01/2026

How Germany’s 2026 sepsis quality rules change reimbursement, and what diagnostics, AI and workflow technologies must prove to get paid.

26/01/2026

Germany’s Hybrid-DRG system explained: how inpatient and outpatient coding is merged, why it matters, and which MedTech and digital health technologies benefit most.